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Abstract
Objective: Clostridioides difficile infection (CDI) can be prevented through infection prevention practices and antibiotic stewardship.
Diagnostic stewardship (ie, strategies to improve use of microbiological testing) can also improve antibiotic use. However, little is known
about the use of such practices in US hospitals, especially after multidisciplinary stewardship programs became a requirement for US hospital
accreditation in 2017. Thus, we surveyed US hospitals to assess antibiotic stewardship program composition, practices related to CDI, and
diagnostic stewardship.
Methods: Surveys were mailed to infection preventionists at 900 randomly sampled US hospitals between May and October 2017. Hospitals
were surveyed on antibiotic stewardship programs; CDI prevention, treatment, and testing practices; and diagnostic stewardship strategies.
Responses were compared by hospital bed size using weighted logistic regression.
Results: Overall, 528 surveys were completed (59% response rate). Almost all (95%) responding hospitals had an antibiotic stewardship pro-
gram. Smaller hospitals were less likely to have stewardship team members with infectious diseases (ID) training, and only 41% of hospitals
met The Joint Commission accreditation standards for multidisciplinary teams. Guideline-recommended CDI prevention practices were
common. Smaller hospitals were less likely to use high-tech disinfection devices, fecal microbiota transplantation, or diagnostic stewardship
strategies.
Conclusions: Following changes in accreditation standards, nearly all US hospitals now have an antibiotic stewardship program. However,
many hospitals, especially smaller hospitals, appear to struggle with access to ID expertise and with deploying diagnostic stewardship strat-
egies. CDI prevention could be enhanced through diagnostic stewardship and by emphasizing the role of non–ID-trained pharmacists and
clinicians in antibiotic stewardship.
(Received 2 August 2019; accepted 14 October 2019; electronically published 6 December 2019)
Unnecessary and inappropriate antibiotic use leads to antibiotic
resistance and one of the most common and deadly healthcare-
associated infections: Clostridioides difficile infection (CDI).1,2
Clostridioides difficile accounts for nearly half a million infections
and 15,000 deaths annually in the United States (US) alone.3 The
US government has used a combination of financial incentives,
public reporting, and regulatory oversight to try to reduce
healthcare-associated infections. Although these policies have
led to decreases in most healthcare-associated infections, CDI
and deaths from CDI have not decreased.4,5
Successful strategies for reducing CDI include antibiotic ste-
wardship and infection prevention.6 For example, England imple-
mented a national CDI prevention campaign in 2007 emphasizing
both antibiotic stewardship and infection prevention. That program
reducedCDI and relatedmortality by at least 60%.7 Although theUS
has adoptedmany infection preventionmeasures, it has been slower
to adopt antibiotic stewardship. In a 2013 national survey, we found
that although infection prevention practices for CDI were nearly
universal in US hospitals, only 52% had an antibiotic stewardship
program.8 The same year, an analysis of the National Healthcare
Safety Network Annual Hospital Survey found that only 39% of
US hospitals met all of the Centers for Disease Control and
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Prevention (CDC) “core elements” for antibiotic stewardship
programs.9 This deficit in antibiotic stewardship is concerning given
mounting data suggesting that antibiotic stewardship plays a larger
role than infection prevention in reducing CDI.10
To address the continued problem of antibiotic overuse and
CDI, the major hospital accrediting body in the US, The Joint
Commission, made antibiotic stewardship programs a condition
for hospital accreditation as of January 1, 2017. Specifically, The
Joint Commission began requiring hospitals to have multidiscipli-
nary stewardship teams including the following, when available:
(1) an infectious diseases (ID) physician, (2) an infection prevention-
ist, (3) a pharmacist, and (4) a practitioner (not defined; presumed in
this analysis to include any physician).11 Concurrently, the US is fac-
ing a shortage of available ID specialists, especially those with anti-
biotic stewardship expertise.12 Whether all US hospitals, especially
smaller hospitals that may have limited resources and staffing, have
been able to meet The Joint Commission goal is not known. This
concern led the CDC to recommend that critical access hospitals
(<25 beds) include a pharmacist and a “physician leader” on their
stewardship team.13
Furthermore, since our 2013 survey, the concept of “diagnostic
stewardship”—or strategies and policies to improve appropriate
use of microbiological testing—has expanded as a key method
to improve antibiotic use.14 Similarly, the adoption of many meth-
ods to prevent, treat, and improve testing for CDI, has not been
well characterized. In 2017, we conducted a random survey of
US hospitals to determine the following: (1) the presence and com-
position of antibiotic stewardship programs; (2) current methods
of CDI prevention, treatment, and testing; (3) diagnostic steward-
ship practices; and (4) whether antibiotic stewardship program
composition, CDI prevention strategies, and diagnostic steward-
ship vary by hospital bed size.
Methods
Data collection
The current study was part of an ongoing survey in which, every
4 years, we ask infection preventionists across the US what practices
their hospitals are using to prevent common healthcare-associated
infections.8,15–17 Survey methods have been previously described.16
Briefly, we randomly sampled 900 medical and surgical hospitals
with an intensive care unit across the US. Three hospitals were
excluded from the study due to closure or status change. Surveys
were mailed in May 2017, with subsequent reminders to nonres-
ponders. Hospitals that employed >1 infection preventionist were
asked to have the lead infection preventionist serve as the primary
respondent, though we encouraged consulting with others to com-
plete the questionnaire. Hospital characteristics, including bed size
and The Joint Commission accreditation status, were obtained by
linking to the 2013 American Hospital Association database.
Institutional review board approval as an exempt studywas obtained
from the University of Michigan.
Survey measures
Similar to prior surveys,15–17 participants were queried regarding
hospital characteristics and details of their infection prevention pro-
grams. In addition, participants were asked how frequently certain
CDI prevention practices were used in their facility (responses: 1
[never] to 5 [always]).8 We defined responses of 4 or 5 (ie, “almost
always” or “always”) as regular use of the respective CDI prevention
practices.Hospitalswere alsoasked, “Hasyourhospital implemented
a urine culture stewardship initiative? (Yes/No)” and “Does your
hospital have an antibiotic stewardship program? (Yes/No).” If par-
ticipants answered yes to having an antibiotic stewardship program,
they were asked to indicate who of the following was on their anti-
biotic stewardship team: (1) infectionpreventionist, (2) IDphysician,
(3) hospitalist (primarily inpatient general internist), (4) other physi-
cian, (5) pharmacist (with ID training), (6) pharmacist (without ID
training), (7) nurse, or (8) other.
Data analysis
To create nationally representative estimates, survey responses are
shown as weighted proportions, with sampling weights based on
the inverse probability of selection and response by bed size. To
evaluate whether antibiotic stewardship program composition
and CDI strategies varied by bed size, we used weighted logistic
regression with hospital bed size as a continuous variable. Odds
ratios are reported for every 10-bed increase. For ease of visualiza-
tion, responses were separated into 3 commonly used bed-size cat-
egories: <50 beds (small), 50–250 beds (medium), >250 beds
(large). P< .05 was considered statistically significant. We used
SAS version 9.4 software (SAS Institute, Cary, NC) for all analyses.
Role of the funding source
The funders of the study had no role in the study design; data col-
lection, analysis, or interpretation; writing of the report; or in the
decision to submit the paper for publication. The corresponding
author had full access to all study data and had final responsibility
for the decision to submit for publication.
Results
The survey response rate was 59% (530 of 897). Two responding
hospitals (0.2%) could not be linked to bed size data and were
excluded, leaving 528 hospitals in the final analysis. Hospital char-
acteristics are shown in Table 1.
Antibiotic stewardship team composition
Nearly all (95%) hospitals reported having an antibiotic steward-
ship program. Most stewardship teams had a pharmacist (99%), a
physician (95%, including ID physician [69%], hospitalist [48%],
or other physician [44%]), and/or an infection preventionist
(91%). Team members with ID training were less common: 52%
of antibiotic stewardship programs had an ID-trained pharmacist,
and 69% had an ID physician. Although most hospitals (78%) had
either an ID physician or ID pharmacist, only 43% had both. Less
than half of hospitals (41%) met The Joint Commission accredita-
tion standard (ID physician, infection preventionist, pharmacist,
practitioner); however, most hospitals (95%) met the minimum
standards set by the CDC for critical access hospitals (pharmacist,
physician).
As bed size increased, hospitals were more likely to have anti-
biotic stewardship team members (eg, hospitalists, non-ID physi-
cians, nurses) with ID training (Fig. 1). In contrast, the presence of
generalists on antibiotic stewardship team did not vary by bed size.
Larger hospitals were more likely to meet both The Joint
Commission recommendation for multidisciplinary stewardship
programs and the CDC minimum recommendations for critical-
access hospitals (Table 2).
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CDI prevention, treatment, and testing practices
The reported use of guideline-recommended18 CDI prevention
practices, which have been shown to reduce CDI, was high
(>90%). Furthermore, CDI preventionwas perceived as “important”
or “very important” to hospital leadership in 89% of hospitals
(Table 3). In contrast, use of innovative, “high-tech” methods
for CDI prevention and availability of fecal microbiota transplant
varied, with larger hospitals more likely to report their use. Across
hospitals, methods of testing for CDI varied; approximately half
of hospitals (56%) used polymerase chain reaction (PCR) and
25% used a combination of testing methods. Larger hospitals
were more likely to use PCR and less likely to use toxin or gluta-
mate dehydrogenase antigen enzyme immunoassay (EIA) testing
methods (Table 4).
Diagnostic stewardship practices
Hospitals commonly (91%) reported rejecting formed stool that
was submitted for CDI testing; however, the use of urine culture
stewardship was uncommon (33%). Both diagnostic stewardship
practices increased with higher bed size (Table 4).
Discussion
In this large national survey of US hospitals, most hospitals had
an antibiotic stewardship program and used evidence-based CDI
prevention practices. Notably, the number of hospitals reporting
antibiotic stewardship programs has nearly doubled in 4 years,8
coinciding with new US hospital accreditation standards.19
Nevertheless, few hospitals met accreditation standards for multi-
disciplinary teams and ID expertise was limited, particularly as
hospital size decreased. Despite national interest in CDI preven-
tion, practices varied across hospitals, with less use of novel CDI
practices and diagnostic stewardship strategies, especially at small
hospitals.
National society guidelines in the US have long recommended
antibiotic stewardship as a key tool for CDI prevention.20 However,
the use of antibiotic stewardship programs has been limited.8 Our
survey revealed that antibiotic stewardship programs have become
nearly universal following new national accreditation require-
ments. The Joint Commission is the top hospital accreditation
body (accrediting 75% of hospitals in our survey), and this uptake
in stewardship is likely related to the 2017 standard. Furthermore,
although hospitals struggled to meet the specific 2017 Joint
Commission recommendation for multidisciplinary antibiotic
stewardship programs, nearly all hospitals had multidisciplinary
stewardship teams, often including a pharmacist, a physician,
and an infection preventionist.
Despite the critical role of pharmacists in antibiotic steward-
ship, only half of US hospitals reported having pharmacists with
ID training. Specialized pharmacy training programs are a more
recent development and training spots are in short supply,21 poten-
tially limiting access to ID pharmacists, especially at smaller hos-
pitals. Instead, clinical pharmacists without ID training often
develop local expertise to improve antibiotic prescribing or
obtaining additional training in stewardship through national
organizations. Similarly, data suggest that antibiotic stewardship
programs are best led by ID physicians with additional stewardship
training.11,22 In our study, two-thirds of hospitals had ID physi-
cians on their stewardship teams. Lack of ID-trained leaders at
small hospitals may limit antibiotic stewardship: in 2015, only
31% of hospitals with ≤50 beds met all CDC core elements.23
Although systematic changes to attract trainees to the field of
ID and to antibiotic stewardship may help, this is a long-term sol-
ution.24,25 Other options to help distribute ID expertise across hos-
pitals include access to expertise through quality collaboratives26 or
“tele-stewardship” in which antibiotic use data are collected
remotely and ID physicians are available via a stewardship “hot-
line.”27 The Infectious Diseases Society of America suggests teleste-
wardship as a way to provide cost-effective subspecialty care to
resource-limited populations.28,29 Unfortunately, many systems
are prevented from using telestewardship due to medico-legal bar-
riers and lack of financial reimbursement.30
Even with these strategies, the numbers of ID physicians spe-
cializing in antibiotic stewardship for all US acute-care hospitals,
outpatient clinics, and long-term care facilities are insufficient.
To account for this shortage, the CDC instead recommends that
each critical access hospital (<25 beds) have, at minimum, a
pharmacist and physician on its stewardship team.13 In our sur-
vey, most small hospitals were able to meet this recommendation
by having a non-ID physician, such as a hospitalist, on their
stewardship team. Hospitalists can play a role in antibiotic stew-
ardship because they prescribe most antibiotics for hospitalized
patients, they can improve frontline provider buy-in, and they
are often engaged in complementary quality improvement
efforts.31–33 Similarly, the role of nurses in antibiotic and diagnos-
tic stewardship is underappreciated but growing.34 A stewardship
model that relies on pharmacy and physician generalists and
nurses could apply not only to small hospitals, but to outpatient
and long-term care settings where availability of ID experts are
limited.
In addition to antibiotic stewardship, infection prevention
strategies are critical in preventing CDI and are often
Table 1. Hospital Characteristics
Variable No.
Acute care beds, mean (95% CI) 216 (199–234)
Intensive care beds, mean (95% CI) 16 (14–17)
Affiliated with a medical school, % (95% CI)a 26 (22–30)
Have a hospital epidemiologist, % (95% CI)a 41 (37–46)
Full-time equivalents for infection preventionists,
mean (95% CI)a
1.8 (1.6–2.1)
Have hospitalist physicians, % (95% CI) 84 (80–87)
Hospital payer, % (95% CI)
Not-for-profit 73 (69–77)
Government (nonfederal) 16 (13–19)
For-profit 11 (9–14)






Accredited by The Joint Commission, % (95% CI) 75 (71–79)
Note. CI, confidence interval.
aData on medical school affiliation, presence of a hospital epidemiologist, and full-time
equivalents for infection preventionists were obtained from our survey data. The remaining
data were obtained by linking respondents to the 2013 American Hospital Association
database.
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multidisciplinary. Unlike stewardship, infection prevention has
been a focus of US policies for decades; thus, it is not surprising
that CDI prevention was considered important by hospital leader-
ship and that evidence-based CDI prevention practices were
common. The significance of variation in “high-tech” CDI preven-
tion strategies is unclear because evidence for many of the practices
is mixed and the cost is often quite high. Thus, small hospitals may
be appropriately delaying purchasing expensive new technology
until more evidence supports their use.
The lack of diagnostic stewardship strategies, especially at smaller
hospitals, is concerning. For example, PCR techniques alone are only
recommended to diagnose patients with a high pretest probability of
CDI; even then, a multistep algorithm including toxin is generally
preferred.18 Thus, hospitals should implement diagnostic testing
algorithms to improve CDI diagnostic accuracy. Ideally, such algo-
rithms would include an assessment of symptoms and alternative
causes to determine when testing is necessary. One high-yield
method is automatically rejecting testing for CDI in patients with
formed stools.14 Similarly, urine culture stewardship is key to reduc-
ing inappropriate antibiotic use for asymptomatic bacteriuria.35 Up
to 40% of hospitalized patients treated with antibiotics for presumed
urinary tract infection have asymptomatic bacteriuria.36 Antibiotic
use in this group increases adverse events and prolongs hospitali-
zation without improving outcomes.36














Antibiotic stewardship team combinations
ID physician and ID pharmacist 43 11 36 66 1.06 (1.04–1.08) <.0001
ID physician or ID pharmacist 78 41 77 95 1.12 (1.08–1.16) <.0001
Any Pharmacist 99 99 99 100 1.14 (1.05–1.24) .001
The Joint Commission recommendation: ID physician,
infection preventionist, pharmacist, practitionerc
41 11 39 56 1.02 (1.01–1.04) .004
CDC recommendation for critical access hospitals:
pharmacist, physician
95 89 94 98 1.05 (1.01–1.09) .02
Note. ID, infectious diseases; CDC, Centers for Disease Control and Prevention. Includes hospitals (N= 493) that reported having an antibiotic stewardship program.
aSurvey responses are shown as weighted proportions with sampling weights based on the inverse probability of selection and response by bed size.
bHospital bed size as reported by the American Hospital Association. P< .05 was considered significant.
c“Practitioner” is terminology used by The Joint Commission. For this analysis, ID physicians, hospitalists, and other physicians were included as practitioners.
Fig. 1. Composition of antibiotic stewardship teams, by bed size (n= 493 hospitals). *Indicates statistically significant odds ratio for every 10-bed increase in bed size
(P< .05). Note. ID, infectious diseases.
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Our study has several limitations. First, we relied on self-
reporting. Although infection preventionists are most likely to
know their hospital’s current practices related to CDI, their
responses may not represent true practice. Second, while our
sampling strategy was designed to obtain a nationally representa-
tive sample, it is possible that participating hospitals differed
from nonparticipating hospitals. For example, hospitals with less
developed stewardship and infection prevention teams may
have been less likely to respond. Third, because we did not
collect data on availability of ID specialists, we were unable to
determine whether lack of ID involvement in stewardship at
small hospitals reflected limited access or limited interest by
available ID specialists. Finally, due to the inherent difficulties
with survey methodology we were unable to assess the implemen-
tation of CDI and diagnostic stewardship strategies.
Herein, we have provided a snapshot of antibiotic stewardship
program team composition, CDI strategies, and diagnostic stew-
ardship in US hospitals in the period immediately following the
2017 Joint Commission standard for antibiotic stewardship.
Although nearly all hospitals now have an antibiotic stewardship
program, team compositions differ by hospital size, and most hos-
pitals do not meet ideal recommendations for multidisciplinary
teams. Specifically, smaller hospitals appear to have limited
ID expertise on their stewardship teams and to struggle with
deploying diagnostic stewardship strategies. In addition to




Regular Useb (N= 528), %
Contact precautions for duration of diarrhea 99
Private rooms or cohorting of patients
with CDI
98
Soap and water hand hygiene when exiting
CDI rooms
92
Thorough terminal cleaning and disinfecting
of hospital rooms and equipment used to
care for patients with CDI
99
Routine daily cleaning of high-touch surfaces
in CDI rooms
90
Established surveillance system for
monitoring CDI rates
98
Report CDI rates to direct care providers 90
“Important” or “Very Important” to hospital
leadership to prevent CDIc
89
Note. CDI, Clostridioides difficile infection.
aSurvey responses are shown as weighted proportions with sampling weights based on the
inverse probability of selection and response by bed size.
bRegular use is defined by a score of 4 or 5 on Likert scale.
cQuestion used a Likert scale from 1 (“Not at all important”) to 5 (“Very important”).
















“High-tech” CDI Prevention Practices
Use supplemental no-touch disinfection devices for CDI rooms
(eg, UV germicidal irradiation, hydrogen peroxide vapor)
29 10 26 44 1.035 (1.024–1.046) <.0001
Use real-time methods to assess thoroughness of cleaning/
disinfection of surfaces in CDI rooms (eg, fluorescent marker, ATP)
72 52 72 83 1.035 (1.018–1.052) <.0001
CDI treatment
Offer fecal microbiota transplant for patients with recurrent CDI 32 5 29 50 1.041 (1.027–1.054) <.0001
C. difficile testing strategies
Primary test used for C. difficile
Antigen EIA 3 7 3 0 .911 (.856–.970) .004
Toxin EIA 15 21 14 13 .979 (.964–.995) .009
PCR 56 46 55 62 1.013 (1.001–1.026) .03
Culture/Cytotoxin assay 2 4 2 1 1.005 (0.936–1.078) .90
Some combination of above 25 23 26 25 .999 (.989–1.009) .83
Have a written policy to routinely test for CDI when patients
have diarrhea while on or within several months of taking
antibiotics
35 39 36 30 .987 (.977–.998) .02
Clinicians educated as to when to order C. difficile testing 88 86 88 90 1.004 (.984–1.024) .73
Diagnostic stewardship strategies
Laboratory rejects formed stools submitted for C. difficile
testing
91 77 93 95 1.057 (1.022–1.093) .002
Urine culture stewardship initiative 33 27 32 36 1.011 (1.000–1.022) .04
Note. ATP, adenosine triphosphate; CDI, Clostridioides difficile infection; C. difficile, Clostridioides difficile; EIA, enzyme immunoassay; PCR, polymerase chain reaction; UV, ultraviolet.
aSurvey responses are shown as weighted proportions with sampling weights based on the inverse probability of selection and response by bed size.
bRegular use is defined by a score of 4 or 5 on Likert scale.
cHospital bed size as reported by the American Hospital Association. P< .05 was considered significant.
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implementing diagnostic stewardship, preventing CDI at small
hospitals may be enhanced by emphasizing the role of generalists,
such as clinical pharmacists, nurses, and hospitalists, in antibiotic
stewardship.
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